| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| Other Sizes |
| Targets |
Cridanimod targets multiple pathways. It acts as a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. It is a progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. It is also an interferon inducer.
|
|---|---|
| ln Vitro |
Cridanimod is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. It induces the expression of IFNα and IFNβ. It significantly increases PR expression. It has unique dual pharmacology as a low molecular weight compound.
|
| ln Vivo |
The duration of cridanimod (intramuscular; 1-6 mg; twice weekly) was noticeably greater. IFNα and -β are markedly and dose-dependently increased in mice when treated with crinanimod [1].
Cridanimod can increase progesterone receptor expression, with potential antineoplastic adjuvant activity. Upon intramuscular administration, it is able to induce the expression of PR in endometrial cancer, which could increase the sensitivity of endometrial cancer cells to progestin monotherapy. It has potential in studying hormone-responsive cancers and immune-mediated therapies. |
| Enzyme Assay |
Cridanimod is evaluated in cell-free assays for its ability to bind to STING and activate the TBK1/IRF3 pathway. The compound is incubated with STING protein, and the activation of downstream signaling is measured using biochemical assays. Its ability to induce interferon expression can be assessed using cell-free transcription assays.
|
| Cell Assay |
Cridanimod is assessed in cell-based assays using various cell lines. Cells are treated with Cridanimod, and the expression of IFNα and IFNβ is measured by qPCR or ELISA. Progesterone receptor expression is measured by Western blot analysis. STING pathway activation is assessed by measuring TBK1 and IRF3 phosphorylation.
|
| Animal Protocol |
Animal/Disease Models: Athymic mice with hec50co cells [1]. 1]
Doses: 1, 3, 6 mg Route of Administration: IM; twice weekly Experimental Results: Dramatically prolonged survival. Cridanimod is administered intramuscularly in animal models to evaluate its effects on progesterone receptor expression and antitumor activity. It has been studied in models of endometrial cancer. Efficacy is assessed by measuring PR expression, tumor growth, and immune response markers. |
| ADME/Pharmacokinetics |
Cridanimod has a molecular weight of 267.24 and a molecular formula of C15H11NO4. It has a CAS number of 38609-97-1. The compound is soluble in DMSO. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Cridanimod. The compound is for research use only and is not intended for human therapeutic use. It has been studied for its potential in cancer immunotherapy and hormonal treatment strategies.
|
| References |
|
| Additional Infomation |
Cridanimod belongs to the acridine class of compounds, and its function is similar to that of acridinium. Cridanimod is a small molecule that increases the expression of the progesterone receptor (PR), exhibiting potential adjuvant antitumor activity. After intramuscular injection, crridanimod can induce PR expression in endometrial cancer cells, thereby increasing the sensitivity of endometrial cancer cells to progesterone monotherapy. When used in combination with progesterone, it can eliminate cancer cells by enhancing PR-mediated signaling, thereby inhibiting the release of luteinizing hormone (LH) from the pituitary gland through a negative feedback mechanism, ultimately inhibiting the release of estrogen from the ovary. This can inhibit the growth of estrogen-dependent tumor cells. Furthermore, this drug can also increase the production and release of interferon (IFN) α and β. Progesterone receptor (PR) is frequently downregulated in endometrial cancer, leading to resistance to progesterone-mediated hormone therapy.
Cridanimod is also known as XBIO-101, XBIO101, and Virexxa. It is a small-molecule immunomodulator and interferon inducer. It is a STING agonist. It is not approved for clinical use. |
| Molecular Formula |
C15H11NO3
|
|---|---|
| Molecular Weight |
253.257
|
| Exact Mass |
253.073
|
| CAS # |
38609-97-1
|
| Related CAS # |
58880-43-6 (sodium);38609-97-1 (free acid);
|
| PubChem CID |
38072
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
486.6±34.0 °C at 760 mmHg
|
| Melting Point |
-289ºC (dec.)
|
| Flash Point |
248.1±25.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.657
|
| LogP |
2.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
356
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UOMKBIIXHQIERR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)
|
| Chemical Name |
2-(9-oxoacridin-10(9H)-yl)acetic acid
|
| Synonyms |
Cridanimod XBIO101 CycloferonXBIO-101 Virexxa Cyclopheron XBIO 101
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~493.56 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (8.21 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9485 mL | 19.7426 mL | 39.4851 mL | |
| 5 mM | 0.7897 mL | 3.9485 mL | 7.8970 mL | |
| 10 mM | 0.3949 mL | 1.9743 mL | 3.9485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
